A Phase Ib/IIa Study of INT-210 Capsules in Participants With Active Ulcerative Colitis
18h agoen
From the article
Conditions : Ulcerative Colitis (UC) Interventions : Drug: INT-210 Capsule; Drug: INT-210 Capsule Sponsors : Innatus Therapeutics (Shanghai) Co., Ltd. Recruiting
Continue reading on clinicaltrials.govYou might also wanna read
Managing Gastrointestinal Toxicities from Immune Checkpoint Inhibitors in Cancer Patients
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment but cause gastrointestinal (GI) side effects in up to 40% of patien
mdsc.pe·1d agoExperimental Novartis radiopharma drug shows promise in early study
reuters.com·1mo ago
PICC-2: Toripalimab Plus Celecoxib Improves pCR in dMMR Locally Advanced Colorectal Cancer
OncoDaily·8h ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.